GLUTATHIONE-S-TRANSFERASE EXPRESSION IN THE HUMAN TESTIS AND TESTICULAR GERM-CELL NEOPLASIA

被引:51
作者
KLYS, HS [1 ]
WHILLIS, D [1 ]
HOWARD, G [1 ]
HARRISON, DJ [1 ]
机构
[1] WESTERN GEN HOSP, DEPT RADIAT ONCOL, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND
关键词
D O I
10.1038/bjc.1992.319
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Glutathione S-transferase (GST) isoenzyme expression is altered in a variety of neoplasms and the enzymes are implicated in metabolism of carcinogens and resistance to drugs, including cisplatin. We have studied GST Alpha, Pi, Mu and microsomal isoenzyme expression by immunohistochemistry in normal and cryptorchid testes, intratubal germ cell neoplasia (ITGCN), seminoma and non-seminomatous germ cell tumours. In 16 stage II-IV malignant teratoma intermediate (MTI) both orchidectomy and post-treatment residual surgical masses were studied. All four isoenzymes were strongly expressed in Leydig and Sertoli cells. GST Pi was absent from normal spermatogonia but strongly expressed by the neoplastic gem cells of ITGCN and seminoma. GST Pi was strongly expressed in all elements of teratoma, irrespective of differentiation. There were no qualitative differences in expression between primary and post-chemotherapy metastases. GST Alpha expression in teratoma correlated with epithelial differentiation. GSTs may be important in normal spermatogenesis and protection of germ cells from teratogens and carcinogens. They may have a role in testicular tumour drug resistance but this role is not well defined. GST Pi is a new marker for ITGCN.
引用
收藏
页码:589 / 593
页数:5
相关论文
共 40 条
[1]  
BATATA MA, 1982, CANCER-AM CANCER SOC, V49, P1023, DOI 10.1002/1097-0142(19820301)49:5<1023::AID-CNCR2820490528>3.0.CO
[2]  
2-M
[3]  
BATIST G, 1986, J BIOL CHEM, V261, P5544
[4]  
Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9
[5]   ORCHIECTOMY IN ADVANCED GERM-CELL CANCER FOLLOWING INTENSIVE CHEMOTHERAPY - A COMPARISON OF SYSTEMIC TO TESTICULAR RESPONSE [J].
CHONG, C ;
LOGOTHETIS, CJ ;
VONESCHENBACH, A ;
AYALA, A ;
SAMUELS, M .
JOURNAL OF UROLOGY, 1986, 136 (06) :1221-1223
[6]  
DECLON PC, 1987, BIOCHEM PHARMACOL, V36, P1955
[7]  
EINHORN LH, 1980, CANCER, V46, P1339, DOI 10.1002/1097-0142(19800915)46:6<1339::AID-CNCR2820460607>3.0.CO
[8]  
2-J
[9]   CISPLATIN-BASED CHEMOTHERAPY DOES NOT ELIMINATE THE RISK OF A 2ND TESTICULAR CANCER [J].
FOSSA, SD ;
AASS, N .
BRITISH JOURNAL OF UROLOGY, 1989, 63 (05) :531-534
[10]  
GONDOS B, 1987, SEMIN DIAGN PATHOL, V4, P292